Buf­fett, Di­mon and Be­zos find their mir­a­cle man, charged with fix­ing a bro­ken health­care sys­tem

War­ren Buf­fett, Jamie Di­mon and Jeff Be­zos have found the per­son they think can fix a bro­ken US health­care sys­tem. And they’re go­ing with a Re­nais­sance man.

At­ul Gawande is tak­ing the reins on Ju­ly 9 with a mis­sion to cre­ate a new en­ti­ty un­bound by prof­it goals. And he’s one of the best-known fig­ures in the in­dus­try.

The com­pa­ny — which still doesn’t have a name — will be based in Boston.

Gawande is a sur­geon at Brigham and Women’s Hos­pi­tal, a pro­fes­sor at the Har­vard TH Chan School of Pub­lic Health and Har­vard Med­ical School plus a best­selling au­thor who has penned 4 books. He al­so writes for The New York­er from time to time.

The three ex­ecs from Ama­zon, Berk­shire Hath­away and JP Mor­gan Chase say they know they’re in for a tough chal­lenge, but Gawande has their con­fi­dence.

“We said at the out­set that the de­gree of dif­fi­cul­ty is high and suc­cess is go­ing to re­quire an ex­pert’s knowl­edge, a be­gin­ner’s mind, and a long-term ori­en­ta­tion,” said Be­zos. “At­ul em­bod­ies all three, and we’re start­ing strong as we move for­ward in this chal­leng­ing and worth­while en­deav­or.”

The three busi­ness head­lin­ers have at­tract­ed plen­ty of at­ten­tion with their al­liance on tam­ing health­care costs, and al­so a lot of skep­ti­cism about what they plan to do as well as what they can ac­com­plish. That skep­ti­cism was height­ened by a Wall Street Jour­nal piece out­lin­ing Di­mon’s rapid as­sur­ances to his big health­care clients that he wasn’t set­ting up a ri­val or­ga­ni­za­tion, liken­ing the ven­ture to a group pur­chas­ing or­ga­ni­za­tion.

Pub­licly, though, the three have lament­ed a sys­tem where ram­pant price in­creas­es have left the na­tion with an in­creas­ing­ly heavy fi­nan­cial bur­den, and it’s a dis­cus­sion which bio­phar­ma com­pa­nies have a di­rect in­ter­est in.

We will have to wait and see what Gawande has in mind for trans­form­ing the sys­tem.

Here’s what he had to say to­day:

I’m thrilled to be named CEO of this health­care ini­tia­tive. I have de­vot­ed my pub­lic health ca­reer to build­ing scal­able so­lu­tions for bet­ter health­care de­liv­ery that are sav­ing lives, re­duc­ing suf­fer­ing, and elim­i­nat­ing waste­ful spend­ing both in the US and across the world. Now I have the back­ing of these re­mark­able or­ga­ni­za­tions to pur­sue this mis­sion with even greater im­pact for more than a mil­lion peo­ple, and in do­ing so in­cu­bate bet­ter mod­els of care for all. This work will take time but must be done. The sys­tem is bro­ken, and bet­ter is pos­si­ble.

Im­age: At­ul Gawande Get­ty/Geisinger Health Sys­tem

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Deborah Dunsire. Lundbeck

Deb­o­rah Dun­sire is pay­ing $2B for a chance to leap di­rect­ly in­to a block­buster show­down with a few of the world's biggest phar­ma gi­ants

A year after taking the reins as CEO of Lundbeck, Deborah Dunsire is making a bold bid to beef up the Danish biotech’s portfolio of drugs in what will likely be a direct leap into an intense rivalry with a group of giants now carving up a growing market for new migraine drugs.

Bright and early European time the company announced that it will pay up to about $2 billion to buy Alder, a little biotech that is far along the path in developing a quarterly IV formulation for a CGRP drug aimed at cutting back the number of crippling migraines patients experience each month.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Lisa M. DeAngelis, MSKCC

MSK picks brain can­cer ex­pert Lisa DeAn­ge­lis as its next CMO — fol­low­ing José Basel­ga’s con­tro­ver­sial ex­it

It’s official. Memorial Sloan Kettering has picked a brain cancer expert as its new physician-in-chief and CMO, replacing José Baselga, who left under a cloud after being singled out by The New York Times and ProPublica for failing to properly air his lucrative industry ties.

His replacement, who now will be in charge of MSK’s cutting-edge research work as well as the cancer care delivered by hundreds of practitioners, is Lisa M. DeAngelis. DeAngelis had been chair of the neurology department and co-founder of MSK’s brain tumor center and was moved in to the acting CMO role in the wake of Baselga’s departure.

Penn team adapts CAR-T tech, reengi­neer­ing mouse cells to treat car­diac fi­bro­sis

After establishing itself as one of the pioneer research centers in the world for CAR-T cancer therapies, creating new attack vehicles to eradicate cancer cells, a team at Penn Medicine has begun the tricky transition of using the basic technology for heart repair work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Tal Zaks. Moderna

The mR­NA uni­corn Mod­er­na has more ear­ly-stage hu­man da­ta it wants to show off — reach­ing new peaks in prov­ing the po­ten­tial

The whole messenger RNA field has attracted billions of dollars in public and private investor cash gambled on the prospect of getting in on the ground floor. And this morning Boston-based Moderna, one of the leaders in the field, wants to show off a few more of the cards it has to play to prove to you that they’re really in the game.

The whole hand, of course, has yet to be dealt. And there’s no telling who gets to walk with a share of the pot. But any cards on display at this point — especially after being accused of keeping its deck under lock and key — will attract plenty of attention from some very wary, and wired, observers.

“In terms of the complexity and unmet need,” says Tal Zaks, the chief medical officer, “this is peak for what we’ve accomplished.”

Moderna has two Phase I studies it wants to talk about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

It's not per­fect, but it's a good start: FDA pan­elists large­ly en­dorse Aim­mune's peanut al­ler­gy ther­a­py

Two days after a fairly benign review from FDA staff, an independent panel of experts largely endorsed the efficacy and safety of Aimmune’s peanut allergy therapy, laying the groundwork for approval with a risk evaluation and mitigation strategy (REMS).

Traditionally, peanut allergies are managed by avoidance, but the threat of accidental exposure cannot be nullified. Some allergists have devised a way to dose patients off-label with peanut protein derived from supermarket products to wean them off their allergies. But the idea behind Aimmune’s product was to standardize the peanut protein, and track the process of desensitization — so when accidental exposure in the real world invariably occurs, patients are less likely to experience a life-threatening allergic reaction.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Rit­ter bombs fi­nal PhI­II for sole lac­tose in­tol­er­ance drug — shares plum­met

More than two years ago Ritter Pharmaceuticals managed to find enough silver lining in its Phase IIb/III study — after missing the top-line mark — to propel its lactose intolerance toward a confirmatory trial. But as it turned out, the enthusiasm only set the biotech and its investors up to be sorely disappointed.

This time around there’s little left to salvage. Not only did RP-G28 fail to beat placebo in reducing lactose intolerance symptoms, patients in the treatment group actually averaged a smaller improvement. On a composite score measuring symptoms like abdominal pain, cramping, bloating and gas, patients given the drug had a mean reduction of 3.159 while the placebo cohort saw a 3.420 drop on average (one-sided p-value = 0.0106).

Ear­ly snap­shot of Ad­verum's eye gene ther­a­py sparks con­cern about vi­sion loss

An early-stage update on Adverum Biotechnologies’ intravitreal gene therapy has triggered investor concern, after patients with wet age-related macular degeneration (AMD) saw their vision deteriorate, despite signs that the treatment is improving retinal anatomy.

Adverum, on Wednesday, unveiled 24-week data from the OPTIC trial of its experimental therapy, ADVM-022, in six patients who have been administered with one dose of the therapy. On average, patients in the trial had severe disease with an average of 6.2 anti-VEGF injections in the eight months prior to screening and an average annualized injection frequency of 9.3 injections.

Alex Ar­faei trades his an­a­lyst's post for a new role as biotech VC; Sanofi vet heads to Vi­for

Too often, Alex Arfaei arrived too late. 

An analyst at BMO Capital Markets, he’d meet with biotech or pharmaceutical heads for their IPO or secondary funding and his brain, trained on a biology degree and six years at Merck and Endo, would spring with questions: Why this biomarker? Why this design? Why not this endpoint? Not that he could do anything about it. These execs were coming for clinical money; their decisions had been made and finalized long ago.